Nucleus RadioPharma’s Post

EGFR-m NSCLC: View recent advances in targeted therapies here! | Molecular Testing, Treatment, and Management of EGFR-Mutated NSCLC | 0.75-hour CME/CE | On-Demand Video | #MedEd #cme #Lungcancertreatment #EGFRMutations | https://bit.ly/3Rz1z8O

Automated and streamlined manufacturing of #TILtherapies The use of #tumorinfiltratingTcells (TILs) for #cancertherapy has shown tremendous results, leading to the first FDA approval in early 2024. However, manufacturing TILs is complex and elaborate, with limitations caused by several open steps and the handling of multiple devices. Streamlined manufacturing processes are thus key to ensuring future success. Next month, join Miltenyi Biotec’s Ian Hardy (Director of T Cell Therapy for Personalized Immunotherapy) and Göteborgs universitet’s Lars Ny (Professor of Immuno-Oncology) as they highlight the potential of a novel #TILmanufacturing process for streamlined and automated manufacturing in a single device. Register for this #webinar below:

EGFR-m NSCLC: View recent advances in targeted therapies here! | Molecular Testing, Treatment, and Management of EGFR-Mutated NSCLC | 0.75-hour CME/CE | On-Demand Video | #MedEd #cme #Lungcancertreatment #EGFRMutations | https://bit.ly/3Rz1z8O

Operate freely with our robust offering of ~500 standard cell lines, licensed, well characterized, and annotated for your screening needs. What sets OmniScreen™ apart? ⬇️ ✅Unmatched Selection: Choose from 30+ cancer indications. ✅Versatile Design: Engage in 3D models, drug combination studies, extended incubation & more. ✅Holistic Solution: From composite biomarker analysis to in vivo follow up with our XenoSelect™ panel. ✅Real-time Insights: Access results promptly with our real-time readouts. Unlock a future where your lead therapeutic agents are the next big breakthrough in preclinical drug development! Register by June 13th ➡️https://hubs.la/Q02yF2fP0 #CancerResearch #CellLines #DrugDevelopment

According to Thomas J. Ettrich, MD, Hochschule Neu-Ulm, and coauthors, "NIFE is the first prospective trial demonstrating efficacy of [nanoliposomal irinotecan with fluorouracil and leucovorin] in the first-line therapy setting… and this regimen merits further validation in a larger phase III trial." Learn more: https://lnkd.in/g2QZfxHW

The preliminary results of Phase I of CT071 (NCT05838131) were presented as a poster at the 29th EHA Annual Congress on June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple myeloma (RRMM)" https://lnkd.in/g3R_eYun #eha #eha2024 #rrmm #cartcelltherapy #gprc5d

OrganoidXplore™ now features more panels and flexible options tailored to your research needs. Choose from our Full 50 model panel or newly added Lung Panel, CRC Panel, or craft your research with our Flexible Panel, offering a selection of 20+ models. 🔬 Harness the power of our extensive repository of PDO and PDXO models for precise drug response profiling. ⏰ Now processing up to 50 models in as little as 6 weeks, we provide robust solutions for transformative drug screening results. Space for our expanded panel options is filling up quickly. Register by March 22nd! ➡️ https://bit.ly/3OUdgpd #DrugScreening #CancerResearch #Bioscience

Hope to see you all at #AACR2024 next week! Come check out a poster by our collaborator, Light Chain Biosciences, to see their exciting work including the use of modeling and simulation to support therapeutic development. Poster #5293: "Preclinical development of NI-3201, a PD-L1xCD28 bispecific antibody mediating CD28 costimulation upon PD-L1 blockade" #AACR, #QSP, #MID3, #Modeling, #PKPD, #Bispecifics, #Immunooncology

The preliminary results of Phase I of CT071 (#NCT05838131) were presented as a poster at the 29th #EHA Annual Congress on #June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of #GPRC5D-targeted #CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple #myeloma (RRMM)" https://lnkd.in/gGMHg-pV #Biotech #Celltherapy

The ability to optimise chemotherapy dosage looks toward the horizon of personalised and tailored medicine as a new frontier in oncology. Our application guide shows how #Optimer binders for #chemotherapy drugs enable accurate and sensitive #biosensors for therapeutic drug monitoring. Tested in clinical samples, Optimer assays: -       Meet FDA requirements -       Support multiplex and single-plex assays -       Show cross-validation with HPLC-MS The small size of Optimer allows increased coating density and enhancing signal at the sensor surface making them the go-to reagent for advanced biosensor development. https://lnkd.in/dvi7VANk #PrecisionMedicine #aptamers #cancer